Phio Pharmaceuticals
Yahoo Finance • 12 days ago
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are... Full story
Yahoo Finance • 15 days ago
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
KING OF PRUSSIA, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to el... Full story
Yahoo Finance • last month
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Quince Therapeutics Inc. 431,482,875 0.337 0.2459 0.2623 +0.1323 Phio Ph... Full story
Yahoo Finance • 9 months ago
Phio Pharma stock maintains buy rating as cancer trial advances
Investing.com - H.C. Wainwright has reiterated its buy rating and $14.00 price target on Phio Pharma (NASDAQ:PHIO), representing significant upside from the current price of $2.17. According to InvestingPro data, the stock has shown strong... Full story
Yahoo Finance • 9 months ago
Phio's PH-762 shows positive safety profile in fourth cohort trial
MARLBOROUGH, MASSACHUSETTS - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a $10.6 million market cap biotechnology company whose stock has gained over 22% year-to-date, announced Wednesday that its Safety Monitoring Committee has recommended... Full story
Yahoo Finance • 2 years ago
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story
Yahoo Finance • 2 years ago
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story
Yahoo Finance • 2 years ago
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story
Yahoo Finance • 2 years ago
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story
Yahoo Finance • 2 years ago
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (di... Full story
Yahoo Finance • 3 years ago
Phio CEO to Speak at Wainwright Conference in New York in September
MARLBOROUGH, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in kil... Full story
Yahoo Finance • 3 years ago
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective i... Full story
